Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1b)

NCT ID: NCT05984303

Last Updated: 2023-08-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-30
• Study Completion Date: 2025-08-30

Brief Summary

This clinical trial is a Phase 1, multiple administration, dose-escalasion clinical trial of human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis. The primary objective of this study is to assess the safety of intravenous infusion of human umbilical cord-derived mesenchymal stem cells in patients with decompensated cirrhosis.

Detailed Description

Decompensated cirrhosis has a high overall mortality rate. There is unmet need for safe and alternative therapeutic potions. This clinical trial is a Phase 1, multiple administration, dose-escalasion clinical trial of human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis. The primary objective of this study is to assess the safety of intravenous infusion of human umbilical cord-derived mesenchymal stem cells in patients with decompensated cirrhosis.In order to illustrate the safety and effectiveness of human umbilical cord-derived mesenchymal stem cells and the patient's dose tolerance to human umbilical cord-derived mesenchymal stem cells.

Conditions

Decompensated Cirrhosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Human Umbilical Cord-derived Mesenchymal Stem Cells

Standard of care (SOC) plus a multiple administration and dose-escalasion with 2 cohorts with 3 subjects/cohort who receive doses of 1 and 2 ×10E8 cells. Each person received 3 infusions, 1 week apart, Proceed from lower dose to higher dose if no safety concerns for each cohort.

Group Type: EXPERIMENTAL

Human Umbilical Cord-derived Mesenchymal Stem Cells

Intervention Type: BIOLOGICAL

Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.

Interventions

Human Umbilical Cord-derived Mesenchymal Stem Cells

Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Willing to provide written informed consent;

2. Aged 18 to 75 years (including 18 and 75 years), male or female;

3. Patients diagnosed with decompensated liver cirrhosis based on clinical findings, laboratory tests, imaging findings and/or representative pathological findings (decompensated liver cirrhosis is defined as the occurrence of at least one serious complication, including esophageal and gastric varices bleeding, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis and other serious complications);

4. Child-Turcotte-Pugh (CTP) score 7 to 12 points.

Exclusion Criteria

1. Hepatitis B virus (HBV) DNA ≥ detection limit at the time of screening, or patients with hepatitis B virus-related decompensated liver cirrhosis may discontinue antiviral therapy during the study, or those who with antiviral therapy for HBV for less than 12 months.

2. Hepatitis C virus (HCV) RNA ≥ detection limit at the time of screening, or patients with hepatitis C virus-related decompensated liver cirrhosis not more than 12 months on antiviral therapy.

3. Patients under treatment with corticosteroids for autoimmune hepatitis for less than 6 months.

4. Trans-jugular intrahepatic portosystemic shunts (TIPS) insertion within 6 months prior to study inclusion.

5. Active drinkers with alcohol-related decompensated cirrhosis are unwilling to stop alcohol abuse after inclusion.

6. Patients with biliary obstruction, or portal patients with vein spongiosis.

7. Patients are known with other malignancies within 5 years prior to the signing of ICF, except have had curative therapy of Basal Cell Cancer, Squamous Cell Carcinoma and/or radical resection of Carcinoma in Situ.

Known to have had other malignancies within 5 years prior to signing the informed consent, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ with curable resection.

8. Patients with history of organ transplantation.

9. Patients with severe heart, lung, kidney and blood system diseases.

10. Patients with drug abuse, drug dependence and patients who receive methadone treatment or with psychosis.

11. Patients with history of immunodeficiency disease, including a positive test result for human immunodeficiency virus (HIV) antibodies, or other acquired or congenital immunodeficiency diseases;

12. Pregnant or lactating female. Fertile patients who were unable or unwilling to use effective non-pharmaceutical contraception during the trial and within 6 months after the end of the trial.

13. Patients who had cardiovascular and cerebrovascular events (such as Unstable Angina, Brain Hemorrhage, severe Ischemic Infarction) within 3 months before the first dose；Patients who had Myocardial Infarct or a clinically significant Arrhythmia/Conduction Abnormalities within 12 months before the first dose.

14. Patients with hypersensitivity (allergic to more than two foods or drugs) or with a history of severe allergy, or patients with Severe allergy to a known experimental drug or to any excipient.

15. Patients previously received stem cell therapy or are intolerance to cell therapy;

16. Participants in other clinical trials within the last 3 months.

17. Any other clinical condition which the investigator considers would make the patient unsuitable for the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China

UNKNOWN

Sponsor Role: collaborator

Beijing 302 Hospital

OTHER

Sponsor Role: lead

Responsible Party

Fu-Sheng Wang

Head of Treatment and Research Center for Infectious Diseases, Principle Investigator, Clinical Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Fu-Sheng Wang, MD, PhD

Role: STUDY_CHAIR

Beijing 302 Hospital

Locations

Beijing 302 Hospital

Beijing, , China

Countries

China

Central Contacts

Lei Shi, MD,PhD

Role: CONTACT

shilei302@126.com

86-10-66949623

Fu-Sheng Wang, MD,PhD

Role: CONTACT

fswang302@163.com

86-10-66933332

Facility Contacts

Lei Shi, MD,PhD

Role: primary

shilei302@126.com

86-10-66949623

References

Shi L, Zhang Z, Mei S, Wang Z, Xu Z, Yao W, Liu L, Yuan M, Pan Y, Zhu K, Liu K, Meng F, Sun J, Liu W, Xie X, Dong T, Huang L, Meng F, Fu JL, Li Y, Zhang C, Fan X, Shi M, Zhang Y, Li Y, Xie WF, Zhang P, Wang FS. Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights. Signal Transduct Target Ther. 2025 Jul 29;10(1):238. doi: 10.1038/s41392-025-02318-4.

Reference Type: DERIVED

PMID: 40721581 (View on PubMed)

Other Identifiers

MSC-DLC-1b

Identifier Type: -

Identifier Source: org_study_id